Crown Laboratories Acquires Eclipse Medcorp's Aesthetics Assets

Crown Aesthetics (Crown Laboratories) Acquires Select Assets from Healeon LLC (Bimini Health Tech)

July 23, 2024

Medical Devices

Crown Aesthetics, a Crown Laboratories company, has acquired select assets and technology from Healeon LLC, a subsidiary of Bimini Health Tech, to strengthen its ProGen PRP Eclipse platelet-rich plasma (PRP) offering. The asset purchase expands Crown's PRP device portfolio, supports new product development, and aims to extend Crown's geographic and production capabilities in the regenerative and aesthetic medicine markets.

Crown Laboratories Acquires Xycrobe Therapeutics, Inc.

May 22, 2019

Biotechnology

Crown Laboratories, a privately held skin care company based in Johnson City, Tennessee, has acquired Xycrobe Therapeutics, a developer of skin microbiome-based biotherapeutic technology. Crown plans to integrate Xycrobe’s microbiome platform and scientific team into its R&D organization to expand therapeutic and consumer skin-care capabilities; financial terms were not disclosed.

Encore Acquires Eclipse to Expand UK Event Production Capabilities

November 20, 2025

Media & Entertainment

Encore, a global event production and technology company headquartered in Schiller Park, Illinois, has acquired Eclipse, a Beckenham, United Kingdom–based creative technical production firm founded in 1988. The acquisition strengthens Encore's presence and capabilities in the UK market—adding Eclipse's production, scenic and in-house creative expertise and venue relationships with London hotels and stadiums.

Cushing Terrell Acquires Eclipse Engineering

July 1, 2024

Engineering Services

Multidisciplinary design firm Cushing Terrell has acquired structural engineering firm Eclipse Engineering, bringing Eclipse's regional offices and specialty structural capabilities into Cushing Terrell's platform. Eclipse's leadership will join Cushing Terrell's structural engineering practice to expand capabilities in mass timber, tilt‑up concrete, seismic retrofits, and other specialty services.

Crown Laboratories Acquires Revance Therapeutics

August 12, 2024

Biotechnology

Crown Laboratories, a Hildred Capital portfolio company, completed the acquisition of Revance Therapeutics through a cash tender offer that expired February 4, 2025; the transaction closed on February 6, 2025 and Revance will be delisted from Nasdaq. The deal brings together Crown's skincare and consumer brands with Revance's DAXXIFY, RHA dermal fillers and other aesthetics/therapeutic offerings to expand product portfolio and commercialization capabilities across medical, retail and e-commerce channels.

Crown Laboratories Acquires Keri Brand from GlaxoSmithKline

May 1, 2019

Consumer Products

Crown Laboratories acquired the North American rights to the Keri skin care brand from GlaxoSmithKline and concurrently received an equity investment from Greenspring Associates. Existing investors Hildred Capital Partners and Montreux Equity Partners provided financing in connection with the transaction; financial terms were not disclosed.